Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angeles Alvarez Secord

Showing results (121-130 of 239) with videos related to

Pageof 24
Sort By:
Gynecologic Oncology Research and Practice|January 25, 2017
Disparities in the surgical staging of high-grade endometrial cancer in the United StatesJonathan R Foote, Stephanie Gaillard, Gloria Broadwater, et al.
The American Journal of Hospice & Palliative Care|October 29, 2025
Optimizing Palliative Cancer Surgery Trial Completion: Lessons Learned From Qualitative Content Analysis of S1316 - Comparative Effectiveness Trial for Malignant Bowel ObstructionMohammad Saad Farooq, Neda Amini, Virginia Sun, et al.
Gynecologic Oncology|September 4, 2009
A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group studyJames V Fiorica, John A Blessing, Louis V Puneky, et al.
Gynecologic Oncology|January 22, 2019
The association between progesterone receptor expression and survival in women with adult granulosa cell tumorsAllison M Puechl, James Edwards, Anuj Suri, et al.
Gynecologic Oncology|October 13, 2018
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group studyBradley J Monk, James T Kauderer, Katherine M Moxley, et al.
American Journal of Cancer Research|July 11, 2022
Ipatasertib, an oral AKT inhibitor, inhibits cell proliferation and migration, and induces apoptosis in serous endometrial cancerLindsey Buckingham, Tianran Hao, Jillian O'Donnell, et al.
Gynecologic Oncology Research and Practice|August 31, 2017
Multidisciplinary approach to manage antenatally suspected placenta percreta: updated algorithm and patient outcomesPaula S Lee, Samantha Kempner, Michael Miller, et al.
International Journal of Cancer|July 31, 2009
Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancerPaula S Lee, Vanessa S Teaberry, Amy E Bland, et al.
Gynecologic Oncology|September 10, 2011
The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group studyAngeles Alvarez Secord, Kathleen M Darcy, Alan Hutson, et al.
Gynecologic Oncology|September 9, 2015
A multi-institutional study of outcomes in stage I-III uterine carcinosarcomaElizabeth L Dickson, Rachel Isaksson Vogel, Paola A Gehrig, et al.
Pageof 24

Showing results (121-130 of 239) with videos related to

Sort By:
Pageof 24
Gynecologic Oncology Research and Practice|January 25, 2017
Disparities in the surgical staging of high-grade endometrial cancer in the United StatesJonathan R Foote, Stephanie Gaillard, Gloria Broadwater, et al.
The American Journal of Hospice & Palliative Care|October 29, 2025
Optimizing Palliative Cancer Surgery Trial Completion: Lessons Learned From Qualitative Content Analysis of S1316 - Comparative Effectiveness Trial for Malignant Bowel ObstructionMohammad Saad Farooq, Neda Amini, Virginia Sun, et al.
Gynecologic Oncology|September 4, 2009
A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group studyJames V Fiorica, John A Blessing, Louis V Puneky, et al.
Gynecologic Oncology|January 22, 2019
The association between progesterone receptor expression and survival in women with adult granulosa cell tumorsAllison M Puechl, James Edwards, Anuj Suri, et al.
Gynecologic Oncology|October 13, 2018
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group studyBradley J Monk, James T Kauderer, Katherine M Moxley, et al.
American Journal of Cancer Research|July 11, 2022
Ipatasertib, an oral AKT inhibitor, inhibits cell proliferation and migration, and induces apoptosis in serous endometrial cancerLindsey Buckingham, Tianran Hao, Jillian O'Donnell, et al.
Gynecologic Oncology Research and Practice|August 31, 2017
Multidisciplinary approach to manage antenatally suspected placenta percreta: updated algorithm and patient outcomesPaula S Lee, Samantha Kempner, Michael Miller, et al.
International Journal of Cancer|July 31, 2009
Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancerPaula S Lee, Vanessa S Teaberry, Amy E Bland, et al.
Gynecologic Oncology|September 10, 2011
The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group studyAngeles Alvarez Secord, Kathleen M Darcy, Alan Hutson, et al.
Gynecologic Oncology|September 9, 2015
A multi-institutional study of outcomes in stage I-III uterine carcinosarcomaElizabeth L Dickson, Rachel Isaksson Vogel, Paola A Gehrig, et al.
Pageof 24